European Reference Network for Rare Vascular Diseases (VASCERN): When and how to use intravenous bevacizumab in Hereditary Haemorrhagic Telangiectasia (HHT)?-Reference-Cited by-同舟云学术

European Reference Network for Rare Vascular Diseases (VASCERN): When and how to use intravenous bevacizumab in Hereditary Haemorrhagic Telangiectasia (HHT)?

Published:2022-10 Issue:10 Volume:65 Page:104575
ISSN:1769-7212
Container-title:European Journal of Medical Genetics
language:en
Short-container-title:European Journal of Medical Genetics

Author:

Dupuis-Girod Sophie^ORCID,Shovlin Claire L.,Kjeldsen Anette D.,Mager Hans-Jurgen,Sabba Carlo,Droege Freya,Fargeton Anne-Emmanuelle,Fialla Annette D.,Gandolfi Silvia,Hermann Ruben,Lenato Gennaro M.,Manfredi Guido,Post Marco C.,Rennie Catherine,Suppressa Patrizia,Sure Ulrich,Buscarini Elisabetta,Crocione Claudia,Blom Ria,Botella Luisa Maria,Brocca Fernando,Coxall Caroline,Druckman Karen T.,Erasme Didier,Federici Paolo,Grabowski Christina,Lundgren Mildred,Søderman Tone,Woods Dara

Funder

European Commission

Publisher

Elsevier BV

Subject

Genetics (clinical),Genetics,General Medicine

Reference60 articles.

1. Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of care;Al-Samkari;Blood,2021

2. Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers;Al-Samkari;Orphanet J. Rare Dis.,2019

3. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia;Al-Samkari;J. Intern. Med.,2019

4. An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia;Al-Samkari;Haemoph. Off. J. World Fed. Hemoph.,2020

5. An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study;Al-Samkari;Haematologica,2021

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Thalidomide and Its Analogs in the Treatment of Hereditary Hemorrhagic Telangiectasia: A Systematic Review;Journal of Clinical Medicine;2024-09-12

2. Hepatic manifestations of hereditary haemorrhagic telangiectasia;Liver International;2024-06-07

3. Mutations causing premature termination codons discriminate and generate cellular and clinical variability in HHT;Blood;2024-05-30

4. Hereditary hemorrhagic telangiectasia: from signaling insights to therapeutic advances;Journal of Clinical Investigation;2024-02-15

5. Impact of heterozygous ALK1 mutations on the transcriptomic response to BMP9 and BMP10 in endothelial cells from hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension donors;Angiogenesis;2024-01-31